Showing results (141-150 of 228) with videos related to

Sort By:
Pageof 23
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
European Journal of Breast Health|October 5, 2023
Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer ChemopreventionFatma Nihan Akkoc Mustafayev, Diane D Liu, Angelica M Gutierrez, et al.
Breast Cancer Research and Treatment|August 11, 2011
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, et al.
Cancer|June 10, 2011
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinomaShannon N Westin, Charlotte C Sun, Karen H Lu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2008
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlationsM Cristofanilli, P Morandi, S Krishnamurthy, et al.
Clinical & Experimental Metastasis|February 2, 2013
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutationsS Bayraktar, A M Gutierrez-Barrera, H Lin, et al.
Therapeutic Advances in Medical Oncology|December 17, 2021
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trialJean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, et al.
JAMA Network Open|June 25, 2024
Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast ConservationKerollos Nashat Wanis, Henry M Kuerer, Susie X Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trialBanu K Arun, Hyo S Han, Bella Kaufman, et al.
NPJ Breast Cancer|May 10, 2022
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancersXuan Liu, Zhongqi Ge, Fei Yang, et al.
Pageof 23